Effect of Combination Nicotinic Acid and Gemfibrozil Treatment on Intermediate Density Lipoprotein, and Subclasses of Low Density Lipoprotein and High Density Lipoprotein in Patients With Combined Hyperlipidemia

American Journal of Cardiology

Volumn 103, Issue 3, 2009, Pages 387-392

  Superko, H Robert ^a,b,d   Garrett, Brenda C ^a   King III, Spencer B ^a,b   Momary, Kathryn M ^a,b   Chronos, Nicolas A ^a   Wood, Peter D ^c  

^a Saint Joseph's Translational Research Institute   (United States)

^b MERCER UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Cholesterol Genetics and Heart Disease Institute ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FAMILIAL COMBINED HYPERLIPIDEMIA; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION;

ADOLESCENT; ADULT; AGED; ANTILIPEMIC AGENTS; APOLIPOPROTEINS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GEMFIBROZIL; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, IDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; NIACIN; TRIGLYCERIDES; YOUNG ADULT;

EID: 58949105022     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.09.103     Document Type: Article

References (28)

1. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., and Motulsky A.G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52 (1973) 1544-1568
2. Hokanson J.E., Austin M.A., Zambon A., and Brunzell J.D. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 13 (1993) 427-434
3. Krauss R.M. Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. Am Heart J 113 (1987) 578-582
4. Johansson J., Carlson L.A., Landow C., and Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb Vasc Biol 11 (1991) 174-1825
5. Superko H.R., Berneis K.K., Williams P.T., Rizzo M., and Wood P.D. Differential effect of gemfibrozil in normolipemic subjects with predominantly dense or buoyant low density lipoprotein particles and the effect on postprandial lipemia and Lp(a). Am J Cardiol 96 (2005) 1266-1272
6. Superko H.R., McGovern M.E., Raul E., and Garrett B. Nicotinic acid has a differential effect on low density lipoprotein subclass distribution in patients classified as LDL pattern A, B, or I. Am J Cardiol 94 (2004) 588-594
7. Brown G.B., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
8. Asztalos B.F., Batista M., Horvath K.V., Cox C.E., Dallal G.E., Morse J.S., Brown G.B., and Schaefer E.J. Change in a1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 23 (2003) 847-852
9. Carlson L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 258 (2005) 94-114
10. Fruchart J.C., Staels B., and Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 3 (2001) 83-92
11. United States Department of Health, Education, and Welfare. Lipid Research Clinics Manual of Laboratory Operations: Lipid and Lipoprotein Analysis, Vol. I. HEW Publication No. NIH 75-628 (1974), United States Government Printing Office, Washington, District of Columbia
12. Warnick G.R., Benderson J., and Albers J.J. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem 28 (1982) 1379-1388
13. Lindgren F.T., Jensen L.C., and Hatch F.T. The isolation and quantitative analysis of serum lipoproteins. In: Nelson G.J. (Ed). Blood Lipids and Lipoproteins: Quantitation, Composition and Metabolism (1972), Wiley-Interscience, New York 181-274
14. Hogle D.M., Smith R.S., and Curtiss L.K. Quantitation of plasma apolipoprotein A-I using two monoclonal antibodies in an enzyme-linked immunosorbent assay. J Lipid Res 29 (1988) 1221-1229
15. Young S.G., Smith R.S., Hogle D.M., Curtiss L.K., and Witztum J.L. Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B. Clin Chem 32 (1986) 1484-1490
16. St-Pierre A.C., Cantin B., Dagenais G.R., Despres J.P., and Lamarche B. Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. Am J Cardiol 97 (2006) 997-1001
17. Whtney E.J., Krasuski R.A., Personium B.E., Michalek J.E., Maranian A.M., Kolasa M.W., Monick E., Brown B.G., and Gotto A.M. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 142 (2005) 95-104
18. Superko H.R. Lipoprotein subclasses and atherosclerosis. Front Biosci 6 (2001) d355-d365
19. Phillips N.R., Waters D., and Havel R.J. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 88 (1993) 2762-2770
20. Gardner C.D., Fortmann S.P., and Krauss R.M. Small low density lipoprotein particles are associated with the incidence of coronary artery disease in men and women. JAMA 276 (1996) 875-881
21. Stampfer M.J., Krauss R.M., Blanche P.J., Holl L.G., Sacks F.M., and Hennekens C.H. A prospective study of triglyceride level, low density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276 (1996) 882-888
22. Lamarche B., Tchernof A., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., and Despres J.P. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec cardiovascular study. Circulation 95 (1997) 69-75
23. Miller N.E., Hammett G., Saltissi S., Rao S., Zeller H.V., Coltart J., and Lewis B. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J 282 (1981) 1741-1744
24. Superko H.R., Krauss R.M., and Alderman E.M. Diabetics have rapid arteriographic coronary disease progression but also arteriographic benefit from risk reduction. Circulation 96 (1997) 4289
25. Superko H.R., and Krauss R.M. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 95 (1992) 69-76
26. McKenney J.M., Jones P.H., Bays H.E., Knopp R.H., Kashyap M.L., Ruoff G.E., and McGovern M.E. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 192 (2007) 432-437
27. Sniderman A.D., Jungner I., Holme I., Aastveit A., and Walldius G. Errors that result from using TC/HDLC ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med 259 (2006) 455-461
28. Guerin M., Bruckert E., Dolphin P.J., Turpin G., and Chapman M.J. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 16 (1996) 763-772